Related Experiment Video

Updated: May 18, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Role of additional novel therapies in myeloproliferative neoplasms

Warren Fiskus1, Siddhartha Ganguly, Suman Kambhampati

  • 1The University of Kansas Medical Center, 3901 Rainbow Boulevard, Robinson Hall 4030, Mail Stop 1027, Kansas City, KS 66160, USA.

Hematology/Oncology Clinics of North America
|September 27, 2012
PubMed

Insights

Novel therapies targeting Janus kinase (JAK) and other pathways offer new hope for advanced myeloproliferative neoplasms (MPN). This review explores emerging treatments beyond JAK inhibitors for improved patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Advanced myeloproliferative neoplasms (MPN) are characterized by constitutive activation of the JAK-STAT signaling pathway.
  • Ruxolitinib approval and development of other JAK inhibitors mark a new era in MPN therapy.

Purpose of the Study:

  • To review novel therapeutic agents for advanced MPN beyond JAK inhibitors.
  • To discuss agents targeting additional signaling pathways and epigenetic mechanisms in MPN.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of emerging therapeutic strategies for MPN.

Main Results:

  • Several novel therapeutic agents are in development for MPN.
  • These agents target pathways beyond JAK/STAT and address epigenetic dysregulation.

Conclusions:

  • Novel therapies, including non-JAK inhibitors, show promise for improving clinical outcomes in advanced MPN.
  • Targeting diverse signaling and epigenetic mechanisms broadens therapeutic options for MPN patients.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...